The Genetic and Molecular Pathogenesis of NF1 and NF2

Seminars in Pediatric Neurology

Volumn 13, Issue 1, 2006, Pages 21-26

  Yohay, Kaleb H ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

merlin; neurofibromatosis; neurofibromin; NF1; NF2; RAC; RAS

Indexed keywords

MERLIN; NEUROFIBROMIN; RAC PROTEIN; RAS PROTEIN;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; CANCER THERAPY; GENE FUNCTION; GENE LOCUS; GENETIC ANALYSIS; HUMAN; MOLECULAR BIOLOGY; NEUROFIBROMATOSIS; NONHUMAN; ONCOGENE; PATHOGENESIS; PHAKOMATOSIS; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; GENES, TUMOR SUPPRESSOR; HUMANS; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 1; NEUROFIBROMIN 2;

EID: 33745486561     PISSN: 10719091     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spen.2006.01.007     Document Type: Article

References (102)

1. Lazaro C., Ravella A., Gaona A., et al. Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father. N Engl J Med 331 (1994) 1403-1407
2. Littler M., and Morton N.E. Segregation analysis of peripheral neurofibromatosis (NF1). J Med Genet 27 (1990) 307-310
3. Evans D.G., Huson S.M., Donnai D., et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity J Med Genet 29 (1992) 841-846
4. Riccardi V.M., and Lewis R.A. Penetrance of von Recklinghausen neurofibromatosis. a distinction between predecessors and descendants. Am J Hum Genet 42 (1988) 284-289
5. Cnossen M.H., van der Est M.N., Breuning M.H., et al. Deletions spanning the neurofibromatosis type 1 gene. implications for genotype-phenotype correlations in neurofibromatosis type 1?. Hum Mutat 9 (1997) 458-464
6. Kayes L.M., Burke W., Riccardi V.M., et al. Deletions spanning the neurofibromatosis 1 gene. identification and phenotype of five patients. Am J Hum Genet 54 (1994) 424-436
7. Ruttledge M.H., Andermann A.A., Phelan C.M., et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 59 (1996) 331-342
8. Baser M.E., Kuramoto L., Joe H., et al. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2. a population-based study. Am J Hum Genet 75 (2004) 231-239
9. Evans D.G., Huson S.M., Donnai D., et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling J Med Genet 29 (1992) 847-852
10. Basu T.N., Gutmann D.H., Fletcher J.A., et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356 (1992) 713-715
11. Gijtenbeek J.M., Gabreels-Festen A.A., Lammens M., et al. Mononeuropathy multiplex as the initial manifestation of neurofibromatosis type 2. Neurology 56 (2001) 1766-1768
12. Wallace M.R., Marchuk D.A., Andersen L.B., et al. Type 1 neurofibromatosis gene. identification of a large transcript disrupted in three NF1 patients. Science 249 (1990) 181-186
13. DeClue J.E., Papageorge A.G., Fletcher J.A., et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69 (1992) 265-273
14. Li Y., Bollag G., Clark R., et al. Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell 69 (1992) 275-281
15. Heim R.A., Silverman L.M., Farber R.A., et al. Screening for truncated NF1 proteins. Nat Genet 8 (1994) 218-219
16. Viskochil D., Buchberg A.M., Xu G., et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62 (1990) 187-192
17. Xu G.F., O'Connell P., Viskochil D., et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62 (1990) 599-608
18. Shen M.H., Harper P.S., and Upadhyaya M. Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet 33 (1996) 2-17
19. Cawthon R.M., Andersen L.B., Buchberg A.M., et al. cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene. Genomics 9 (1991) 446-460
20. Cawthon R.M., O'Connell P., Buchberg A.M., et al. Identification and characterization of transcripts from the neurofibromatosis 1 region. the sequence and genomic structure of EVI2 and mapping of other transcripts. Genomics 7 (1990) 555-565
21. Viskochil D., Cawthon R., O'Connell P., et al. The gene encoding the oligodendrocyte-myelin glycoprotein is embedded within the neurofibromatosis type 1 gene. Mol Cell Biol 11 (1991) 906-912
22. Gutmann D.H., Wood D.L., and Collins F.S. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci U S A 88 (1991) 9658-9662
23. DeClue J.E., Cohen B.D., and Lowy D.R. Identification and characterization of the neurofibromatosis type 1 protein product. Proc Natl Acad Sci U S A 88 (1991) 9914-9918
24. Bollag G., McCormick F., and Clark R. Characterization of full-length neurofibromin. tubulin inhibits Ras GAP activity. EMBO J 12 (1993) 1923-1927
25. Gutmann D.H., and Collins F.S. The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron 10 (1993) 335-343
26. Daston M.M., Scrable H., Nordlund M., et al. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron 8 (1992) 415-428
27. Gregory P.E., Gutmann D.H., Mitchell A., et al. Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat Cell Mol Genet 19 (1993) 265-274
28. Suzuki Y., Suzuki H., Kayama T., et al. Brain tumors predominantly express the neurofibromatosis type 1 gene transcripts containing the 63 base insert in the region coding for GTPase activating protein-related domain. Biochem Biophys Res Commun 181 (1991) 955-961
29. Nishi T., Lee P.S., Oka K., et al. Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation. Oncogene 6 (1991) 1555-1559
30. Malhotra R., and Ratner N. Localization of neurofibromin to keratinocytes and melanocytes in developing rat and human skin. J Invest Dermatol 102 (1994) 812-818
31. Heim R.A., Silverman L.M., Farber R.A., et al. Screening for truncated NF1 proteins. Nat Genet 8 (1994) 218-219
32. Friedman J.M. Epidemiology of neurofibromatosis type 1. Am J Med Genet 89 (1999) 1-6
33. Riccardi V.M. Molecular biology of the neurofibromatoses. Semin Dermatol 12 (1993) 266-273
34. Easton D.F., Ponder M.A., Huson S.M., et al. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1). evidence for modifying genes. Am J Hum Genet 53 (1993) 305-313
35. Heim R.A., Kam-Morgan L.N., Binnie C.G., et al. Distribution of 13 truncating mutations in the neurofibromatosis 1 gene. Hum Mol Genet 4 (1995) 975-981
36. Park V.M., and Pivnick E.K. Neurofibromatosis type 1 (NF1). a protein truncation assay yielding identification of mutations in 73% of patients. J Med Genet 35 (1998) 813-820
37. Messiaen L.M., Callens T., Mortier G., et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 15 (2000) 541-555
38. Frahm S., Mautner V.F., Brems H., et al. Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. Neurobiol Dis 16 (2004) 85-91
39. Kai S., Sumita H., Fujioka K., et al. Loss of heterozygosity of NF1 gene in juvenile chronic myelogenous leukemia with neurofibromatosis type 1. Int J Hematol 68 (1998) 53-60
40. Gutmann D.H., Cole J.L., Stone W.J., et al. Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I. Genes Chromosomes Cancer 10 (1994) 55-58
41. Gutmann D.H., Donahoe J., Brown T., et al. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol 26 (2000) 361-367
42. Gutmann D.H., James C.D., Poyhonen M., et al. Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology 61 (2003) 1397-1400
43. Colman S.D., Williams C.A., and Wallace M.R. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet 11 (1995) 90-92
44. Sawada S., Florell S., Purandare S.M., et al. Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat Genet 14 (1996) 110-112
45. Serra E., Puig S., Otero D., et al. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet 61 (1997) 512-519
46. Kluwe L., Friedrich R., and Mautner V.F. Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. Genes Chromosomes Cancer 24 (1999) 283-285
47. Guran S., and Safali M. A case of neurofibromatosis and breast cancer. loss of heterozygosity of NF1 in breast cancer. Cancer Genet Cytogenet 156 (2005) 86-88
48. Cacev T., Radosevic S., Spaventi R., et al. NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer. Gut 54 (2005) 1129-1135
49. Martinsson T., Sjoberg R.M., Hedborg F., et al. Homozygous deletion of the neurofibromatosis-1 gene in the tumor of a patient with neuroblastoma. Cancer Genet Cytogenet 95 (1997) 183-189
50. Ingram D.A., Yang F.C., Travers J.B., et al. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 191 (2000) 181-188
51. Rizvi T.A., Akunuru S., de Court, et al. Region-specific astrogliosis in brains of mice heterozygous for mutations in the neurofibromatosis type 1 (Nf1) tumor suppressor. Brain Res 816 (1999) 111-123
52. Nordlund M.L., Rizvi T.A., Brannan C.I., et al. Neurofibromin expression and astrogliosis in neurofibromatosis (type 1) brains. J Neuropathol Exp Neurol 54 (1995) 588-600
53. Gutmann D.H., Loehr A., Zhang Y., et al. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene 18 (1999) 4450-4459
54. Bajenaru M.L., Donahoe J., Corral T., et al. Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia 33 (2001) 314-323
55. Gutmann D.H., Wu Y.L., Hedrick N.M., et al. Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes. Hum Mol Genet 10 (2001) 3009-3016
56. Bos J.L. ras oncogenes in human cancer. a review. Cancer Res 49 (1989) 4682-4689
57. Bollag G., and McCormick F. Differential regulation of rasGAP and neurofibromatosis gene product activities. Nature 351 (1991) 576-579
58. Bollag G., Clapp D.W., Shih S., et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12 (1996) 144-148
59. Feldkamp M.M., Lau N., Provias J.P., et al. Acute presentation of a neurogenic sarcoma in a patient with neurofibromatosis type 1: a pathological and molecular explanation. Case report. J Neurosurg 84 (1996) 867-873
60. The I., Hannigan G.E., Cowley G.S., et al. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science 276 (1997) 791-794
61. Johnson M.R., Look A.T., DeClue J.E., et al. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP. Ras. Proc Natl Acad Sci U S A 90 (1993) 5539-5543
62. Zang K.D. Cytological and cytogenetical studies on human meningioma. Cancer Genet Cytogenet 6 (1982) 249-274
63. Rouleau G.A., Wertelecki W., Haines J.L., et al. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 329 (1987) 246-248
64. Rouleau G.A., Merel P., Lutchman M., et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363 (1993) 515-521
65. Trofatter J.A., MacCollin M.M., Rutter J.L., et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72 (1993) 791-800
66. Kluwe L., Friedrich R.E., Hagel C., et al. Mutations and allelic loss of the NF2 gene in neurofibromatosis 2-associated skin tumors. J Invest Dermatol 114 (2000) 1017-1021
67. Hung G., Faudoa R., Baser M.E., et al. Neurofibromatosis 2 phenotypes and germ-line NF2 mutations determined by an RNA mismatch method and loss of heterozygosity analysis in NF2 schwannomas. Cancer Genet Cytogenet 118 (2000) 167-168
68. Lamszus K., Vahldiek F., Mautner V.F., et al. Allelic losses in neurofibromatosis 2-associated meningiomas. J Neuropathol Exp Neurol 59 (2000) 504-512
69. Lasota J., Wozniak A., Kopczynski J., et al. Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs). a study on 50 cases. Lab Invest 85 (2005) 237-247
70. Ueki K., Wen-Bin C., Narita Y., et al. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 59 (1999) 5995-5998
71. Pylkkanen L., Sainio M., Ollikainen T., et al. Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region. Oncol Rep 9 (2002) 955-959
72. Lamszus K., Lachenmayer L., Heinemann U., et al. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int J Cancer 91 (2001) 803-808
73. Lomas J., Bello M.J., Arjona D., et al. Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. Genes Chromosomes Cancer 42 (2005) 314-319
74. Kino T., Takeshima H., Nakao M., et al. Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes Cells 6 (2001) 441-454
75. Gonzalez-Gomez P., Bello M.J., Alonso M.E., et al. CpG island methylation in sporadic and neurofibromatis type 2-associated schwannomas. Clin Cancer Res 9 (2003) 5601-5606
76. Parry D.M., Eldridge R., Kaiser-Kupfer M.I., et al. Neurofibromatosis 2 (NF2). clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52 (1994) 450-461
77. Zhao Y., Kumar R.A., Baser M.E., et al. Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2). Genet Epidemiol 23 (2002) 245-259
78. Baser M.E., Ragge N.K., Riccardi V.M., et al. Phenotypic variability in monozygotic twins with neurofibromatosis 2. Am J Med Genet 64 (1996) 563-567
79. Parry D.M., MacCollin M.M., Kaiser-Kupfer M.I., et al. Germ-line mutations in the neurofibromatosis 2 gene. correlations with disease severity and retinal abnormalities. Am J Hum Genet 59 (1996) 529-539
80. Baser M.E., Kuramoto L., Woods R., et al. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J Med Genet 42 (2005) 540-546
81. Maccollin M., Ramesh V., Jacoby L.B., et al. Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet 55 (1994) 314-320
82. Tsukita S., Yonemura S., and Tsukita S. ERM proteins. head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem Sci 22 (1997) 53-58
83. Pearson M.A., Reczek D., Bretscher A., et al. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell 101 (2000) 259-270
84. Kang B.S., Cooper D.R., Devedjiev Y., et al. The structure of the FERM domain of merlin, the neurofibromatosis type 2 gene product. Acta Crystallogr D Biol Crystallogr 58 (2002) 381-391
85. Shimizu T., Seto A., Maita N., et al. Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain. J Biol Chem 277 (2002) 10332-10336
86. Sherman L., Xu H.M., Geist R.T., et al. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15 (1997) 2505-2509
87. Gutmann D.H., Haipek C.A., and Hoang L.K. Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations. J Neurosci Res 58 (1999) 706-716
88. Sherman L., Xu H.M., Geist R.T., et al. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15 (1997) 2505-2509
89. Gutmann D.H., Geist R.T., Xu H., et al. Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet 7 (1998) 335-345
90. McClatchey A.I., Saotome I., Ramesh V., et al. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev 11 (1997) 1253-1265
91. McClatchey A.I., Saotome I., Mercer K., et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 12 (1998) 1121-1133
92. Giovannini M., Robanus-Maandag E., Niwa-Kawakita M., et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev 13 (1999) 978-986
93. Kalamarides M., Niwa-Kawakita M., Leblois H., et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16 (2002) 1060-1065
94. Schulze K.M., Hanemann C.O., Muller H.W., et al. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum Mol Genet 11 (2002) 69-76
95. Fraenzer J.T., Pan H., Minimo Jr. L., et al. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 23 (2003) 1493-1500
96. Morrison H., Sherman L.S., Legg J., et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15 (2001) 968-980
97. Ikeda K., Saeki Y., Gonzalez-Agosti C., et al. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J Neurosurg 91 (1999) 85-92
98. Tikoo A., Varga M., Ramesh V., et al. An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem 269 (1994) 23387-23390
99. Xiao G.H., Chernoff J., and Testa J.R. NF2. the wizardry of merlin. Genes Chromosomes Cancer 38 (2003) 389-399
100. Kissil J.L., Wilker E.W., Johnson K.C., et al. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 12 (2003) 841-849
101. Rong R., Tang X., Gutmann D.H., et al. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A 101 (2004) 18200-18205
102. Ryu C.H., Kim S.W., Lee K.H., et al. The merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity. Oncogene 24 (2005) 5355-5364